Applying Non-Homogeneous Dose Optimization to Improve Conventionally Fractionated Radiation Plan Quality in Patients with Non-Small Cell Lung Cancer

Sarah Z. Hazell, Russell Hales, William T. Hrinivich, Kristy Ford, Ken Kang-Hsin Wang, Todd McNutt, Peijin Han, Lori J. Anderson, Adam C. Ferro, Joseph Moore, Khinh Voong

Research output: Contribution to journalArticle

Abstract

Purpose: Nonhomogeneous dose optimization (NHDO) is exploited in stereotactic body radiation therapy (SBRT) to increase dose delivery to the tumor and allow rapid dose falloff to surrounding normal tissues. We investigate changes in plan quality when NHDO is applied to inverse-planned conventionally fractionated radiation therapy (CF-RT) plans in patients with non-small cell lung cancer. Methods and Materials: Patients with near-central non-small cell lung cancer treated with CF-RT in 2018 at a single institution were identified. CF-RT plans were replanned using NHDO techniques, including normalizing to a lower isodose line, while maintaining clinically acceptable normal tissue constraints and target coverage. Tumor control probabilities were calculated. We compared delivered CF-RT plans using homogenous dose optimization (HDO) versus NHDO using Wilcoxon signed-rank tests. Median values are reported. Results: Thirteen patients were replanned with NHDO techniques. Planning target volume coverage by the prescription dose was similar (NHDO = 96% vs HDO = 97%, P =.3). All normal-tissue dose constraints were met. NHDO plans were prescribed to a lower-prescription isodose line compared with HDO plans (85% vs 97%, P =.001). NHDO increased mean dose to the planning target volume (73 Gy vs 67 Gy), dose heterogeneity, and dose falloff gradient (P <.03). NHDO decreased mean dose to surrounding lungs, esophagus, and heart (relative reduction of 6%, 14%, and 15%, respectively; P <.05). Other normal tissue objectives improved with NHDO, including total lung V40 and V60, heart V30, and maximum esophageal dose (P <.05). Tumor control probabilities doubled from 31.6% to 65.4% with NHDO (P =.001). Conclusions: In select patients, NHDO principles used in SBRT optimization can be applied to CF-RT. NHDO results in increased tumor dose, reduction in select organ-at-risk dose objectives, and better maintenance of target coverage and normal-tissue constraints compared with HDO. Our data demonstrate that principles of NHDO used in SBRT can also improve plan quality in CF-RT.

Original languageEnglish (US)
JournalPractical Radiation Oncology
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Non-Small Cell Lung Carcinoma
Radiotherapy
Radiation
Prescriptions
Neoplasms
Organs at Risk
Lung
Nonparametric Statistics
Esophagus
Maintenance

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Applying Non-Homogeneous Dose Optimization to Improve Conventionally Fractionated Radiation Plan Quality in Patients with Non-Small Cell Lung Cancer. / Hazell, Sarah Z.; Hales, Russell; Hrinivich, William T.; Ford, Kristy; Kang-Hsin Wang, Ken; McNutt, Todd; Han, Peijin; Anderson, Lori J.; Ferro, Adam C.; Moore, Joseph; Voong, Khinh.

In: Practical Radiation Oncology, 01.01.2019.

Research output: Contribution to journalArticle

Hazell, Sarah Z. ; Hales, Russell ; Hrinivich, William T. ; Ford, Kristy ; Kang-Hsin Wang, Ken ; McNutt, Todd ; Han, Peijin ; Anderson, Lori J. ; Ferro, Adam C. ; Moore, Joseph ; Voong, Khinh. / Applying Non-Homogeneous Dose Optimization to Improve Conventionally Fractionated Radiation Plan Quality in Patients with Non-Small Cell Lung Cancer. In: Practical Radiation Oncology. 2019.
@article{bcdb5c9c2a7d4444a1dbf32a04887468,
title = "Applying Non-Homogeneous Dose Optimization to Improve Conventionally Fractionated Radiation Plan Quality in Patients with Non-Small Cell Lung Cancer",
abstract = "Purpose: Nonhomogeneous dose optimization (NHDO) is exploited in stereotactic body radiation therapy (SBRT) to increase dose delivery to the tumor and allow rapid dose falloff to surrounding normal tissues. We investigate changes in plan quality when NHDO is applied to inverse-planned conventionally fractionated radiation therapy (CF-RT) plans in patients with non-small cell lung cancer. Methods and Materials: Patients with near-central non-small cell lung cancer treated with CF-RT in 2018 at a single institution were identified. CF-RT plans were replanned using NHDO techniques, including normalizing to a lower isodose line, while maintaining clinically acceptable normal tissue constraints and target coverage. Tumor control probabilities were calculated. We compared delivered CF-RT plans using homogenous dose optimization (HDO) versus NHDO using Wilcoxon signed-rank tests. Median values are reported. Results: Thirteen patients were replanned with NHDO techniques. Planning target volume coverage by the prescription dose was similar (NHDO = 96{\%} vs HDO = 97{\%}, P =.3). All normal-tissue dose constraints were met. NHDO plans were prescribed to a lower-prescription isodose line compared with HDO plans (85{\%} vs 97{\%}, P =.001). NHDO increased mean dose to the planning target volume (73 Gy vs 67 Gy), dose heterogeneity, and dose falloff gradient (P <.03). NHDO decreased mean dose to surrounding lungs, esophagus, and heart (relative reduction of 6{\%}, 14{\%}, and 15{\%}, respectively; P <.05). Other normal tissue objectives improved with NHDO, including total lung V40 and V60, heart V30, and maximum esophageal dose (P <.05). Tumor control probabilities doubled from 31.6{\%} to 65.4{\%} with NHDO (P =.001). Conclusions: In select patients, NHDO principles used in SBRT optimization can be applied to CF-RT. NHDO results in increased tumor dose, reduction in select organ-at-risk dose objectives, and better maintenance of target coverage and normal-tissue constraints compared with HDO. Our data demonstrate that principles of NHDO used in SBRT can also improve plan quality in CF-RT.",
author = "Hazell, {Sarah Z.} and Russell Hales and Hrinivich, {William T.} and Kristy Ford and {Kang-Hsin Wang}, Ken and Todd McNutt and Peijin Han and Anderson, {Lori J.} and Ferro, {Adam C.} and Joseph Moore and Khinh Voong",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.prro.2019.06.010",
language = "English (US)",
journal = "Practical Radiation Oncology",
issn = "1879-8500",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Applying Non-Homogeneous Dose Optimization to Improve Conventionally Fractionated Radiation Plan Quality in Patients with Non-Small Cell Lung Cancer

AU - Hazell, Sarah Z.

AU - Hales, Russell

AU - Hrinivich, William T.

AU - Ford, Kristy

AU - Kang-Hsin Wang, Ken

AU - McNutt, Todd

AU - Han, Peijin

AU - Anderson, Lori J.

AU - Ferro, Adam C.

AU - Moore, Joseph

AU - Voong, Khinh

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Purpose: Nonhomogeneous dose optimization (NHDO) is exploited in stereotactic body radiation therapy (SBRT) to increase dose delivery to the tumor and allow rapid dose falloff to surrounding normal tissues. We investigate changes in plan quality when NHDO is applied to inverse-planned conventionally fractionated radiation therapy (CF-RT) plans in patients with non-small cell lung cancer. Methods and Materials: Patients with near-central non-small cell lung cancer treated with CF-RT in 2018 at a single institution were identified. CF-RT plans were replanned using NHDO techniques, including normalizing to a lower isodose line, while maintaining clinically acceptable normal tissue constraints and target coverage. Tumor control probabilities were calculated. We compared delivered CF-RT plans using homogenous dose optimization (HDO) versus NHDO using Wilcoxon signed-rank tests. Median values are reported. Results: Thirteen patients were replanned with NHDO techniques. Planning target volume coverage by the prescription dose was similar (NHDO = 96% vs HDO = 97%, P =.3). All normal-tissue dose constraints were met. NHDO plans were prescribed to a lower-prescription isodose line compared with HDO plans (85% vs 97%, P =.001). NHDO increased mean dose to the planning target volume (73 Gy vs 67 Gy), dose heterogeneity, and dose falloff gradient (P <.03). NHDO decreased mean dose to surrounding lungs, esophagus, and heart (relative reduction of 6%, 14%, and 15%, respectively; P <.05). Other normal tissue objectives improved with NHDO, including total lung V40 and V60, heart V30, and maximum esophageal dose (P <.05). Tumor control probabilities doubled from 31.6% to 65.4% with NHDO (P =.001). Conclusions: In select patients, NHDO principles used in SBRT optimization can be applied to CF-RT. NHDO results in increased tumor dose, reduction in select organ-at-risk dose objectives, and better maintenance of target coverage and normal-tissue constraints compared with HDO. Our data demonstrate that principles of NHDO used in SBRT can also improve plan quality in CF-RT.

AB - Purpose: Nonhomogeneous dose optimization (NHDO) is exploited in stereotactic body radiation therapy (SBRT) to increase dose delivery to the tumor and allow rapid dose falloff to surrounding normal tissues. We investigate changes in plan quality when NHDO is applied to inverse-planned conventionally fractionated radiation therapy (CF-RT) plans in patients with non-small cell lung cancer. Methods and Materials: Patients with near-central non-small cell lung cancer treated with CF-RT in 2018 at a single institution were identified. CF-RT plans were replanned using NHDO techniques, including normalizing to a lower isodose line, while maintaining clinically acceptable normal tissue constraints and target coverage. Tumor control probabilities were calculated. We compared delivered CF-RT plans using homogenous dose optimization (HDO) versus NHDO using Wilcoxon signed-rank tests. Median values are reported. Results: Thirteen patients were replanned with NHDO techniques. Planning target volume coverage by the prescription dose was similar (NHDO = 96% vs HDO = 97%, P =.3). All normal-tissue dose constraints were met. NHDO plans were prescribed to a lower-prescription isodose line compared with HDO plans (85% vs 97%, P =.001). NHDO increased mean dose to the planning target volume (73 Gy vs 67 Gy), dose heterogeneity, and dose falloff gradient (P <.03). NHDO decreased mean dose to surrounding lungs, esophagus, and heart (relative reduction of 6%, 14%, and 15%, respectively; P <.05). Other normal tissue objectives improved with NHDO, including total lung V40 and V60, heart V30, and maximum esophageal dose (P <.05). Tumor control probabilities doubled from 31.6% to 65.4% with NHDO (P =.001). Conclusions: In select patients, NHDO principles used in SBRT optimization can be applied to CF-RT. NHDO results in increased tumor dose, reduction in select organ-at-risk dose objectives, and better maintenance of target coverage and normal-tissue constraints compared with HDO. Our data demonstrate that principles of NHDO used in SBRT can also improve plan quality in CF-RT.

UR - http://www.scopus.com/inward/record.url?scp=85070683059&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070683059&partnerID=8YFLogxK

U2 - 10.1016/j.prro.2019.06.010

DO - 10.1016/j.prro.2019.06.010

M3 - Article

JO - Practical Radiation Oncology

JF - Practical Radiation Oncology

SN - 1879-8500

ER -